Acute and Chronic Effect of Teriparatide on Glucose Metabolism in Women with Established Osteoporosis

A. Anastasilakis; D. G. Goulis; G. Koukoulis; M. Kita; A. Slavakis; A. Avramidis

doi:10.1055/s-2007-967090

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2007; 115(2): 108-111
DOI: 10.1055/s-2007-967090

Article

Acute and Chronic Effect of Teriparatide on Glucose Metabolism in Women with Established Osteoporosis

A. Anastasilakis¹ , D. G. Goulis¹ , G. Koukoulis¹ , M. Kita¹ , A. Slavakis¹ , A. Avramidis¹

¹Department of Endocrinology, Hippocration General Hospital, Thessaloniki, Greece

Abstract

There is indirect evidence of unfavorable effects of parathyroid hormone (PTH) on glucose metabolism. Teriparatide (recombinant human PTH 1-34-TPTD) has recently been available for the treatment of osteoporosis. The aim of this prospective study was to evaluate the acute and chronic effect of TPTD on blood glucose and insulin levels in women with established osteoporosis. Twenty-three postmenopausal women with established osteoporosis (mean age 65.6±1.8 years) received daily injections of 20 mg TPTD for six months. Three oral glucose tolerance tests (OGTT) were performed: one day before the first injection (OGTT-basal), one hour after (OGTT-acute) and six months after initiation of therapy (OGTT-chronic). There were significant differences between the OGTT-basal and OGTT-acute values in glucose at 90 min (168.3±9.8 vs. 180.6±9.2, p<0.05) and 120 min (152.0±8.7 vs. 170.5±7.8, p<0.01), between the OGTT-basal and OGTT-chronic values for glucose at 90 min (168.3±9.8 vs. 184.5±13.3, p<0.05) and between the OGTT-basal and OGTT-acute for insulin at 90 min (56.7±7.4 vs. 68.7±8.2, p<0.01). These differences remained significant for the subgroup of patients with normal (n=8) but not impaired glucose tolerance or diabetes mellitus (n=15). TPTD seems to have an acute, subclinical adverse impact on stimulated glucose levels, possibly due to insulin resistance. This impact tends to subside when TPTD is continued on a chronic basis.

Key words

teriparatide - glucose metabolism - diabetes mellitus - impaired glucose tolerance - parathyroid hormone

Full Text

References

1 Chiu KC, Chuang LM, Lee NP, Ryu JM, McGullam JL, Tsai GP, Saad MF. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism. 2000; 49 1501-1505
2 Fadda GZ, Akmal M, Lipson LG, Massry SG. Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Physiol. 1990; 258 975-984
3 Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, Ritz E. Sub-acute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997; 12 933-938
4 Kumar S, Olukoga AO, Gordon C, Mawer EB, France M, Hosker JP, Davies M, Boulton AJ. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf). 1994; 40 47-53
5 Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985; 60 229-233
6 Nowicki M, Fliser D, Fode P, Ritz E. Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. J Clin Endocrinol Metab. 1996; 81 156-159
7 Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R. Peripheral insulin resistance in primary hyperparathyroidism. Metabolism. 1983; 32 800-805
8 Prager R, Schernthaner G, Kovarik J, Cichini G, Klaushofer K, Willvonseder R. Primary hyperparathyroidism is associated with decreased insulin receptor binding and glucose intolerance. Calcif Tissue Int. 1984; 36 253-258
9 Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003; 26 1136-1142
10 Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med. 2002; 19 958-961
11 Richards ML, Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy?. Surgery. 1999; 126 1160-1166
12 Saxe AW, Gibson G, Gingerich RL, Levy J. Parathyroid hormone decreases in vivo insulin effect on glucose utilization. Calcif Tissue Int. 1995; 57 127-132
13 Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hy-perparathyroidism. Diabetes Metab Res Rev. 2001; 17 175-180
14 Thomas DM, Rogers SD, Sleeman MW, Pasquini GM, Bringhurst FR, Ng KW, Zajac JD, Best JD. Modulation of glucose transport by parathyroid hormone and insulin in UMR 106-01, a clonal rat osteogenic sarcoma cell line. J Mol Endocrinol. 1995; 14 263-275
15 Valdermarsson S, Leckstrom A, Westermark P, Bergenfelz A. Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism. Eur J Endocrinol. 1996; 134 320-325
16 Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2001; 54 805-811
17 Zablocki K, Michalik M, Bryla J. Substrate-dependent effect of 1-34 human parathyroid hormone fragment, dibutyryl cAMP and cAMP on gluconeogenesis in rabbit renal tubules. Biochim Biophys Acta. 1986; 886 483-490

Correspondence

A. Anastasilakis

Soulini 4

566 25 Sykies

Greece

Phone: + 30 2310 63 90 27

Fax: + 30 2310 83 99 00

Email: anastath@endo.gr